The Calcium-dependent Myoblast Adhesion that Precedes Cell Fusion Is Mediated by Glycoproteins

KAREN A. KNUDSEN
The Wistar Institute, Philadelphia, Pennsylvania, 19104. Dr. Knudsen's present address is The Lankenau Medical Research Center, Philadelphia, Pennsylvania 19151.

ABSTRACT Presumptive myoblasts from explants of chick embryo pectoral muscle proliferate, differentiate, and fuse to form multinucleate myotubes. One event critical to multinucleate cell formation is the specific adhesion of myoblasts before union of their membranes. In the studies reported here five known inhibitors of myotube formation—trifluoperazine, sodium butyrate, chloroquine, 1,10 phenanthroline, and tunicamycin—were tested for their effect on the Ca++-dependent myoblast adhesion step. The first four inhibitors of myotube formation do not perturb myoblast adhesion but rather block fusion of aggregated cells, which suggests that these agents perturb molecular events required for the union of the lipid bilayers. By contrast, tunicamycin exerts its effect by inhibiting the myoblast adhesion step, thereby blocking myotube formation. The effect of tunicamycin can be blocked by a protease inhibitor, however, which implies that the carbohydrate residues protect the glycoproteins from proteolytic degradation rather than participate directly in cell-cell adhesion. Whereas trypsin treatment of myoblasts in the absence of Ca++ destroys the cells' ability to exhibit Ca++-dependent adhesion, the presence of Ca++ during trypsin treatment inhibits the enzyme's effect, which suggests that myoblast adhesion is mediated by a glycoprotein(s) that has a conformation affected by Ca++. Finally, myoblast adhesion is inhibited by an antiserum raised against fusion-competent myoblasts. The effect of the antiserum is blocked by a fraction from the detergent extract of pectoral muscle that binds to immobilized wheat germ agglutinin, which again suggests that glycoproteins mediate Ca++-dependent myoblast adhesion.

Embryonic muscle can be excised from 11-d chicks, enzymatically dissociated, filtered, and grown in culture. The resulting presumptive myoblasts proliferate, differentiate, align in culture, and fuse to form multinucleate myotubes that express the biochemical and morphological characteristics of muscle (4, 7; reviewed in 3, 23, 46). This progression of orderly and timed events is accompanied by regulated expression of new molecules, migration of cells, adhesion of myoblasts, and union of cell membranes.

To shed light on the molecular nature of the events that occur during the formation of multinucleate cells, investigators have sought means to inhibit the easily recognizable event of myotube formation. Several agents and conditions that have been found to block myotube formation include EDTA (45), cytochalasin B (24), lectins (13), phospholipase C (38), lyssolecithin (48), exogenously added cholesterol (57), inhibition of endogenous cholesterol synthesis in cells grown in lipid-depleted medium (8), and enrichment of elaidate (trans-oleate) in the cellular membrane (25). More recently five other agents have been added to the growing list of inhibitors of myotube formation: trifluoperazine (TFP) (1), an antagonist of the calcium-binding protein calmodulin (30, 36); chloroquine (28), a lysomotropic amine that inhibits the function of lysosomal enzymes (42) and alters the turnover of receptors (19, 29); 1,10 phenanthroline, a metal chelator that inhibits soluble metalloendoproteases in myoblasts (9, 10); sodium butyrate (15), a short chain fatty acid that may modify the cell membrane; and tunicamycin (18), an inhibitor of dolichol-phosphate-mediated glycosylation of proteins at asparagine-linked sites. Taken together the results of these numerous inhibitor studies have led investigators to the general conclusions that calcium, proteins and glycoproteins, lipids, and the cytoskeleton are all somehow involved in myoblast fusion.
To understand a cellular process as complex as myogenesis on a molecular level, it is necessary to dissect it into steps that can be manipulated experimentally. One such step central to myogenesis is the recognition and adhesion of fusion-competent myoblasts. Previous work by Knudsen and Horwitz (32) showed that cultured myoblasts express an enhanced ability to adhere to one another in suspension at the same time that they express an optimal ability to fuse. The adhesion depends on Ca ++ (as does myotube formation) and is specific (32). The existence of Ca ++-dependent myoblast adhesion and, in addition, Ca ++-independent adhesion has recently been confirmed by the work of Gibralter and Turner (17). Earlier, Knudsen and Horwitz had shown that the Ca ++-dependent myoblast adhesion displays optima for pH, temperature, Ca ++ concentration, and age of cell culture that closely parallel those for myotube formation (32). Inhibitor studies by the same authors showed that some agents able to inhibit myotube formation—such as energy poisons, trypsin, an inhibitor of cholesterol synthesis, and inhibitors of protein synthesis—block myoblast adhesion, whereas other inhibitors of myotube formation, such as cytochalasin B, colchicine, phospholipase C, or enrichment of membranes in elaidate, have no effect on myoblast adhesion (33). Taken together, these results led Knudsen and Horwitz to conclude that a separate, distinct adhesion event that depends on Ca ++ and involves cell surface proteins precedes the fusion of myoblast membranes.

The studies reported here extend our understanding of the nature of the molecules involved in the specific, Ca ++-dependent myoblast adhesion step of myogenesis. A preliminary report of this work has been published in abstract form (31).

MATERIALS AND METHODS

Materials: TFP, chloroquine (diphosphate salt), 1,10-phenanthroline, leupeptin, and cycloheximide were purchased from Sigma Chemical Co. (St. Louis, MO). Tunicamycin was from Boehringer Mannheim Biochemicals (Indianapolis, IN). Sodium butyrate was from J. T. Baker Chemical Co. (Phillipsburg, NJ). These reagents were stored according to the manufacturer's instructions and dissolved immediately before use, except for tunicamycin, which was stored at -70°C as a 500 ~g/ml stock solution in H2O/dimethyl sulfoxide, 1:1. Optimal times of addition to the culture medium and optimal concentrations of the agents being tested were determined experimentally to be those that blocked the myotube formation initiated by adding Ca ++ to 52-h EGT A-blocked cultures without causing cellular toxicity, as determined by morphological examination of the cells by phase-contrast microscopy and trypan blue exclusion.

Cell Culture: Primary cultures of pectoral muscle cells and fibroblasts were prepared from 11- to 12-d chick embryos as described (32). Myoblast cultures were plated on collagen-coated culture dishes at 6 x 10^6 cells/100-mm dish and grown in Ca ++-free Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS), 1% Pen-Strep and 0.5% Fungizone (both from Flow Laboratories, Inc., McLean, VA), and 5 mM HEPES at 37°C in an atmosphere of 90% air/10% CO2. EGT A was added to the cells at a concentration of 200-300 ~M to prevent myoblast fusion.

Harvesting Myoblasts: EGT A-blocked, fusion-competent myoblasts were detached from the substratum 50-51 h after plating by adding a heat-inactivated antiserum that specifically disrupts cell-substratum adhesion of myoblasts. This antiserum was raised in a rabbit against cell surface, integral membrane glycoproteins involved in cell-substratum adhesion (34) purified from chick cells by antibody affinity chromatography using a monoclonal antibody (CSAT) that rounds and detaches myoblasts from a variety of substrata but does not interfere with myoblast fusion (26, 40). A maximum effect in a reasonable amount of time resulted when the antiserum was added at dilutions of from 1:200 to 1:500 3 to 4 h before the aggregation assays. The rounded myoblasts were removed from the culture dish by gentle pipetting, concentrated by centrifugation, and resuspended in Ca ++-free Hank's balanced salt solution containing 5% glucose, 10 mM HEPES, and, when indicated, 1 mM Ca ++.

Production of Rabbit Antiserum against Fusion-Competent Myoblasts: EGT A-blocked myoblasts were harvested 52 h after plating using the cell-substratum, adhesion-perturbing rabbit antiserum described above. Approximately 10^6 cells were washed with phosphate-buffer saline (PBS), pelleted by centrifugation, resuspended in 0.5 ml PBS, mixed 1:1 with either complete (first injection) or incomplete Freund's adjuvant, and injected subcutaneously in four sites in a rabbit. Four injections were given at 2-wk intervals before the rabbit was bled and the heat-inactivated serum was tested for its effect on myoblast aggregation and myotube formation.

Assays for Myoblast Aggregation: Myoblast aggregation was determined on 52-h cultures by two assays. In one assay, the cell concentration was adjusted to 2.5-3.0 x 10^6 cells/ml and 1-ml aliquots were mixed in 5-ml Fernbach flasks for 20 min at 37°C on an Adams Nutator (Clay Adams, Parsippany, NJ). At this cell concentration, the clusters that formed were small enough to permit counting of the aggregated myoblasts. The percentage of aggregated cells was scored by counting cells using phase-contrast microscopy as previously described (32).

In the second aggregation assay, the cell concentration was adjusted to 1 x 10^6 cells/ml and 0.5-ml aliquots were mixed in wells of a 24-well Costar dish (Costar, Cambridge, MA) at 37°C for 20 min on the Nutator. At this concentration, the cells formed large clusters composed of too many cells to count by microscopic observation. Instead, the results were recorded by photography. For both assays the inhibitors, when tested, were present during the incubation period.

Assay for Myoblast Fusion: To measure myobute formation, 1-2 mM Ca ++ was added to EGT A-blocked cultures 50-52 h after plating, and fusion was quantitated 18-20 h later as previously described (32). To assess fusion of myoblasts aggregated in suspension, the cells mixed at a concentration of 1 x 10^6 cells/ml for 20 min at 37°C were transferred to the wells of six-well Costar dishes (not collagen coated) and incubated in 2.5 ml of fresh medium overnight at 37°C in either the absence or presence of the inhibitors and/or Ca ++. No attempt was made to wash away any remaining cell-substratum adhesion-perturbing antibody. Fusion of cells in suspension, i.e., myoball formation (33), was scored by microscopic observation using an inverted phase-contrast microscope and by recording the results photographically. Multinucleate cell formation was confirmed by exposing the cells to 0.1% trypsin and 1 mM EDTA in PBS for 15 min at 37°C and observing under the microscope whether or not this treatment dispersed the cells.

Analysis of Protein Synthesis: Protein synthesis was measured by trichloroacetic acid (TCA) precipitation of radiolabeled cells. 10-15 ~Ci of 1,3-H-amino acid mix (New England Nuclear, Boston, MA) was added to 30-h EGT A-blocked cultures along with tunicamycin (0.1 ~g/ml) or cycloheximide (5 ~g/ml). 52 h after plating the cells, the medium was removed and centrifuged for 10 min at 15,000 rpm in an SS 34 rotor of a Sorvall RC2-B centrifuge (DuPont Instruments, Sorvall Biomedical Div., Wilmington, DE) to collect any cells that had detached from the substratum. Cold 10% TCA was added to the cells on the culture dish and to the few cells that were retrieved from the conditioned medium. The cells were scraped from the dishes with a rubber policeman and washed onto a 0.45-~m filter under vacuum. The cells were collected and washed on the filters and the filters were monitored for radioactivity using the premixed liquid scintillation solution Formula 963 (New England Nuclear).

Pectoral Muscle Extraction and Lectin Affinity Chromatography: Pectoral muscle extracts dissected from 50-100 11-12-d chick embryos or skeletal muscle fibroblasts grown in roller bottles were extracted with Nonidet P-40 detergent using previously described procedures (35), except that the Ca ++ concentration was 1 mM in all buffers. The muscle extract was fractionated by wheat germ agglutinin (WGA) affinity chromatography using described procedures (35). When the various fractions were exposed to cells in an antibody-affinity blocking assay, the detergent was removed using Bio-Beads SM-2 (Bio-Rad Laboratories, Richmond, CA) as described previously (35).

RESULTS

We used five known inhibitors of myotube formation to help elucidate the nature of the molecules responsible for the specific, Ca ++-dependent adhesion of myoblasts. Initially, we had to determine the conditions required to block fusion of EGT A-blocked cultures (initiated by addition of Ca ++*) since these were the myoblasts to be assayed for their ability to aggregate in suspension. Therefore, we tested various concentrations and addition times for tunicamycin, sodium butyrate, chloroquine, TFP, and 1,10-phenanthroline. Consistent with the observations of other investigators, all five agents inhibited
myotube formation (data not shown). The following concentrations and times of addition (hours after plating the cells) were found to be the optimal conditions (i.e., the lowest effective concentration and shortest incubation time) for blocking myotube formation initiated by adding 1–2 mM Ca** to 50–52 h EGTA-blocked myoblasts: chloroquine, 10 μM, 5 h; TFP, 2 μM, 24 h; sodium butyrate, 2 mM, 24 h; tunicamycin, 0.1 μg/ml, 31–34 h; 1,10 phenanthroline, 10 μg/ml, 48 h. Unless otherwise indicated these conditions were then used to assess the effect of the myotube inhibitors on myoblast aggregation.

For aggregation assays, the cells were grown in the presence of EGTA and the myotube inhibitors were added at the concentrations and times described above. Approximately 51 h after plating, the myoblasts to be used in the aggregation assays were detached from the substratum using the adhesion-perturbing antiserum described in Materials and Methods and assayed for their ability to aggregate in both the absence and presence of Ca** as described in Materials and Methods. The antiserum used to harvest the myoblasts neither aggregated the cells in the absence of Ca** during the 20-min incubation nor inhibited their aggregation in the presence of Ca**, even when added to the assay at a 10-fold higher concentration than that used to detach the myoblasts from their substratum (Table I). Thus, antibody-induced agglutination of cells does not occur under the conditions of the assay. Harvesting the cells using the antiserum resulted in an essentially pure myoblast population free of cell surface changes that might occur by detaching the cells with EDTA. Calculated from the results of 17 experiments, the average percentage of aggregated cells in the absence of Ca** was 16% (range, 8–28%) and that in the presence of Ca** was 55% (range, 41–69%). The variability from day to day is not entirely understood but is probably due to the condition of the cells, their precise concentration, and perhaps the expression of the molecules involved in cell-cell adhesion. In any case, the data are most easily understood and compared when they are expressed as a function of the Ca**-plus control (i.e., percent aggregation in treatment divided by percent aggregation in control with Ca** times 100).

Sodium butyrate, chloroquine, TFP, and 1,10 phenanthroline added under conditions that blocked myotube formation all had no effect on Ca**-dependent myoblast aggregation (Table II and Fig. 1), implying that their effectiveness in inhibiting myotube formation is not due to a perturbation of the events involved in myoblast recognition and adhesion. In contrast, tunicamycin prevented the Ca**-dependent adhesion of the myoblasts (Table II and Fig. 1), which suggests that this agent inhibits myotube formation by preventing Ca**-dependent myoblast adhesion. For complete inhibition, the tunicamycin had to be added ~18 h before the aggregation assay. Addition 3–5 h before the aggregation assay resulted in only partial or no inhibition of myoblast aggregation. The effect of tunicamycin is not due to a general inhibition of protein synthesis during the 18–20-h incubation since TCA precipitation of cells metabolically radiolabeled with 3H-amino acids showed little effect on protein synthesis (Table III). On the other hand, treatment with cycloheximide, an inhibitor of both protein synthesis and Ca**+-dependent Ca++-dependent myoblast adhesion (33), during the same period showed a marked reduction in the incorporation of 3H-amino acids into TCA-precipitable counts (Table III). Although tunicamycin prevents myoblast aggregation, its effect can be inhibited by simultaneous addition of the protease inhibitor leupeptin (Table IV), suggesting that the carbohydrate residues protect the glycoproteins from proteolytic degradation.

To determine whether or not the inhibitors that have no effect on myoblast aggregation block fusion of myoblasts after the cells have been aggregated in the presence of Ca**, the myoblast clusters formed at a cell concentration of 1 x 106 cells/ml were incubated overnight at 37°C in the continued presence of the inhibitors. In the control, cells aggregated in the presence of Ca** (and absence of inhibitors) and incubated overnight in Ca++ fused into large multinucleate myoballs (Fig. 2 A) that could not be disrupted by treatment with 1 mM EDTA plus 0.1% trypsin. If we omitted Ca** from the medium during the overnight incubation of aggregates formed in the presence of Ca**, no fusion occurred (Fig. 2 B) and the cells could be dispersed by trypsin. Similarly, cells treated with sodium butyrate, chloroquine, TFP, or 1,10 phenanthroline and aggregated in the presence of Ca** failed to fuse even though Ca** was present during the overnight incubation (Fig. 2 C, E, F, and G). In contrast to the above inhibitors of myotube formation, tunicamycin did not appear to prevent the fusion of cells in small aggregates that formed during the aggregation assay or during the overnight incubation (Fig. 2 D).

Because Ca++ plays such an important role in myogenesis, we further investigated its relationship to the molecules implicated in myoblast adhesion. Knudsen and Horwitz (33) reported that trypsin treatment in the absence of Ca++ of fusion-competent myoblasts destroys their ability to aggregate when Ca++ is restored. Here we note that if 1–10 mM Ca++ is added to the cells 5 min before their treatment with trypsin, the effect of the enzyme is greatly diminished (Table V). This result suggests that a Ca++-initiated conformation may protect the adhesion molecules from the action of trypsin.

Following a now well established paradigm for studying adhesive events in cells (reviewed in reference 11), we raised an antiserum against fusion-competent myoblasts in order to generate antibodies that bind to the adhesion molecules, perturb cell–cell adhesion, and, therefore, act as probes for the presence of adhesion-related molecules. We generated such an antiserum by injecting a rabbit with fusion-competent myoblasts harvested as described in Materials and Methods. The antiserum raised against myoblasts (anti-myo) blocks both Ca++-dependent myoblast aggregation and myotube formation (Table VI). The effect of the antiserum on myoblast aggregation can be blocked by a Nonidet P-40 extract of chick pectoral muscle but not by an extract of cultured chick fibroblasts containing a similar amount of protein (Table VI). Preliminary experiments designed to purify the antiserum-blocking activity revealed that the blocking activity was en-
FIGURE 1  Myoblast aggregation in cultures treated with known inhibitors of myotube formation. EGTA-blocked myoblasts were harvested 51 h after plating and mixed at a concentration of 1 x 10^6 cells/ml in the absence (A) or presence (B) of 1 mM Ca++ at 37°C for 20 min. The following inhibitors were added to the cultures at concentrations and times indicated in the legend to Table II: C, sodium butyrate; D, tunicamycin; E, 1,10 phenanthroline; F, TFP, and G, chloroquine. x 40.

TABLE II. Quantitation of Ca++-dependent Myoblast Aggregation in Cultures Treated with Known Inhibitors of Myotube Formation

| Treatment of cells          | %Ca++ plus control |
|-----------------------------|---------------------|
| 1 mM Ca++                   | 100                 |
| No Ca++                     | 29                  |
| Chloroquine, 1 mM Ca++      | 87                  |
| TFP, 1 mM Ca++              | 93                  |
| 1,10 Phenanthroline, 1 mM Ca++ | 93             |
| Sodium butyrate, 1 mM Ca++  | 100                 |
| Tunicamycin, 1 mM Ca++      | 18                  |

EGTA-blocked myoblasts were harvested 51 h after plating as described in Materials and Methods and mixed at a concentration of 2.5 x 10^6 cells/ml for 20 min at 37°C. Inhibitors were added at the following concentrations and hours after plating: chloroquine, 10 μM at 5 h; TFP, 2 μM at 24 h; tunicamycin, 0.1 μg/ml at 31–34 h; 1,10 phenanthroline, 10 μg/ml at 48 h. The data represent the average of at least three experiments and are expressed as a function of percent aggregation in the presence of Ca++. In the absence of Ca++, the percent aggregation in the presence of the inhibitors was similar to that of the Ca++-minus control.

DISCUSSION

Over the past years, investigators studying myogenesis have reported a number of agents and cell culture conditions that inhibit the in vitro formation of multinucleate muscle cells. These inhibitor studies have helped to define the events leading to myotube formation and to generally implicate calcium (49), proteins (33), glycoproteins (18, 43), lipids (25), and the cytoskeleton (24) as molecules that have roles in the construction of multinucleate muscle cells. The complexity of the process of myotube formation has made it difficult to identify the molecules involved and to understand when in

riched ~10-fold by lectin affinity chromatography using immobilized wheat germ agglutinin. This result is consistent with the hypothesis that the molecules that mediate Ca++-dependent myoblast adhesion are cell surface glycoproteins. Further purification of these glycoproteins is in progress.
the process of myogenesis they are synthesized and used. The mechanism by which calcium promotes myoblast fusion is unknown, as is the exact function of the cytoskeleton. By focusing on the myoblast recognition/adhesion step of myogenesis, it is possible to refine the existing molecular information provided by reagents known to inhibit myotube formation and to begin to understand myogenesis at a molecular level.

**Table III.** Metabolically Incorporated TCA-precipitable Radioactivity in Tunicamycin-treated Cells

| Treatment of cells            | cpm    | % Control |
|-------------------------------|--------|-----------|
| Control                       | 3,786 (7,022) | 100 (100) |
| Tunicamycin (0.1 µg/ml)       | 3,351 (6,447) | 88 (92)   |
| Cycloheximide (5 µg/ml)       | 1,056 (2,157) | 28 (31)   |

Reagents were added to EGTA-blocked cultures 31–32 h after plating and [3H]-amino acid incorporation was assayed as described in Materials and Methods. Numbers in parentheses express the results of a duplicate experiment.

**Table IV.** Effect of the Protease Inhibitor Leupeptin on Tunicamycin Inhibition of Myoblast Aggregation

| Conditions of assay          | %Ca++-plus control |
|-------------------------------|--------------------|
| 1 mM Ca++                    | 100                |
| No Ca++                      | 40                 |
| Tunicamycin, no Ca++         | 27                 |
| Tunicamycin, 1 mM Ca++       | 50                 |
| Leupeptin, no Ca++           | 61                 |
| Leupeptin, 1 mM Ca++         | 91                 |
| Tunicamycin, leupeptin, no Ca++ | 47            |
| Tunicamycin, leupeptin, 1 mM Ca++ | 105             |

Tunicamycin (0.075 µg/ml) and leupeptin (50 µM) were added 31–32 h after plating and were present during the aggregation assay, 51 h after plating the myoblasts were harvested and aggregated under the above conditions as described in Materials and Methods. At higher concentrations of tunicamycin the leupeptin was less effective at protecting against the effect of tunicamycin on myoblast aggregation. The high percentage of aggregation in the presence of leupeptin and absence of Ca++ was observed repeatedly and may mean that leupeptin protects Ca++-independent aggregation against endogenous protease activity.

**Figure 2.** Myoball formation. EGTA-blocked myoblasts were harvested 51 h after plating and mixed at a concentration of $1 \times 10^6$ cells/ml in the presence of Ca++ and the inhibitors that had been added to the cultures at the concentrations and times indicated in the legend to Table II. The aggregates were then incubated overnight in the continued presence of the inhibitors and/or 1 mM Ca++, except in B where Ca++ was omitted. A, no inhibitor; B, no inhibitor (no Ca++); C, sodium butyrate; D, tunicamycin; E, 1,10 phenanthroline; F, TFP; and G, chloroquine. × 40.
Of the five inhibitors of myotube formation tested, only tunicamycin blocks the specific, Ca++-dependent aggregation of fusion-competent myoblasts. This occurs at concentrations that have no effect on overall protein synthesis, even though to block myoblast aggregation totally the inhibitor has to be added ~18 h before the assay. Since addition of tunicamycin 1–5 h before the assay results in only a slight inhibition, we postulate that the adhesion glycoproteins are being synthesized ~34 h after plating the cells and that their expression is maximal a few hours before the EGTA-blocked myoblasts as a population display an optimal ability to adhere and fuse (i.e., 52 h after plating in low Ca++).

The studies reported here indicate that the myotube inhibitors sodium butyrate, chloroquine, TFP, and 1,10-phenanthroline do not exert their effect by preventing the specific adhesion of fusion-competent myoblasts. This conclusion is based on the observation that the inhibitors, when added to cultures at times and concentrations known to block myotube formation, do not block the Ca++-dependent aggregation of myoblasts in suspension. These results suggest, for example, that neither metalloendoproteases nor calmodulin-binding proteins are involved in Ca++-dependent myoblast adhesion.

Rather, all four inhibitors block the fusion of the myoblasts after their adhesion in the presence of Ca++. The mechanisms of action of these agents remain speculative and are best expressed by the authors who first noted their ability to inhibit myotube formation (1, 9, 10, 15, 28).

Simultaneous addition of a protease inhibitor, leupeptin, blocks the effect of tunicamycin on Ca++-dependent myoblast aggregation, which implies, as others have reported (44), that the carbohydrate residues do not participate in the adhesion event, but rather that they protect the glycoproteins from proteolytic degradation. This is consistent with the previous observation of Knudsen and Horwitz (33) that myoblast adhesion is not perturbed by treatment of cells with agents known to perturb carbohydrate residues such as galactose oxidase, mixed glycosidases, and neuraminidase.

Since myoblast aggregation is inhibited by treating cells with trypsin in the absence of Ca++, it seems likely that the protein portion of the glycoprotein(s) is involved in the specific adhesion of the myoblasts. It is possible that the glycoprotein has a Ca++-dependent conformation, since the presence of Ca++ appears to protect the adhesion molecules from degradation by trypsin. Such a Ca++-dependent conformation has been reported for uvomorulin, the cell–cell adhesion molecule involved in early mouse embryogenesis (27).

Together with previous observations, the data presented here suggest that a distinct Ca++-dependent recognition/adhesion event involving surface membrane glycoproteins is necessary, but not sufficient, for myoblast fusion. Molecules that mediate Ca++-dependent adhesion have been implicated in interactions of lung cells (51), fibroblasts (56), neural retina cells (6, 20–22, 37, 53–55), liver cells (2, 5, 16, 41), teratocarcinoma cells (41, 52, 58, 59), epithelial cells (12), and in early embryogenesis (11, 14, 27, 47, 50). Myoblast adhesion differs from that in other cells, however, because it is accompanied by cell fusion. As Neff et al. (39) showed, membrane contiguity is apparent within 20–30 min after myoblast fusion is initiated by the addition of Ca++ to fusion-competent myoaggregates, which suggests that fusion closely follows adhesion. Indeed, it may be that Ca++-dependent adhesion triggers a cascade of events that results in the formation of multinucleate muscle.

In summary, an essential step in myogenesis includes the specific interaction of myoblasts before their fusion. This event requires Ca++ and appears to be mediated by cell surface glycoproteins that may have a Ca++-dependent conformation. After adhesion, the membranes between adjacent cells unite by a process that appears to require a particular lipid composition, the continued presence of Ca++, and the cytoskeleton. These events may be initiated by Ca++-dependent myoblast interaction and may result from a cascade of events triggered by surface glycoproteins that effect cell–cell adhesion.

We thank Drs. George Tuszynski and Caroline Damsky for their helpful comments on the manuscript.

This work was supported by grants HD/CA-15663 and CA19144 from the National Institutes of Health.

Received for publication 27 August 1984, and in revised form 24 April 1985.

REFERENCES
1. Bar-Sagi, D., and J. Prives. 1983. Thioltransferase, a calmodulin antagonist, inhibits muscle cell fusion. J. Cell Biol. 97:1375–1380.
2. Bertoni, R., U. Rutishauser, and G. M. Edelman. 1980. A cell surface molecule involved in aggregation of embryonic liver cells. Proc. Natl. Acad. Sci. USA. 77:4831–4835.
3. Bucknall, R. 1976. Myoblast fusion. In Membrane Fusion. G. Poste and G. L. Nicolson, editors. Elsevier/North-Holland Biomedical Press. New York. 127–179.
4. Bischoff, R., and H. Holtzer. 1969. Mitosis and the process of differentiation of myogenic cells in vitro. J. Cell Biol. 41:188-200.

5. Brackenbury, R. U. Rushe, and G. Edelman. 1981. Distinct calcium-independent and calcium-dependent adhesion systems of chicken embryonic cells. Proc. Natl. Acad. Sci. USA. 78:387-391.

6. Cooper, W. G., and J. L. Lilien. 1982. The accessibility of certain proteins on an embryonic chick neural retina cells in anodization and tretryc removal is altered by calcium. J. Cell Sci. 55:85-103.

7. Cornell, R. S., S. M. Nissley, and A. F. Horwitz. 1980. Cholesterol availability modulates myoblast fusion. J. Cell Biol. 86:820-824.

8. Couch, C. B., and W. J. Strittmatter. 1984. Specific blockers of myoblast fusion inhibit myoblast fusion. Exp. Biol. 90:31-48.

9. Cooper, W. G., and J. L. Lilien. 1983. Calcium and myoblast fusion. Cell. 32:257-265.

10. Cornblath, D. R. 1984. Specific blockers of myoblast fusion inhibit a soluble and not the membrane-associated metalloproteinase in myoblasts. J. Biol. Chem. 259:5390-5399.

11. Den, H., D. Malinzak, H. Keating, and A. Rosenberg. 1975. Influence of concanavalin A, wheat germ agglutinin, and soybean agglutinin on the fusion of myoblasts in vitro. J. Cell Biol. 67:826-834.

12. Ducibella, T., and E. Anderson. 1975. Cell shape and membrane changes in the eight-cell mouse embryo: prerequisites for morphogenesis of the blastocyst. Dev. Biol. 48:45-58.

13. Fiszman, M. Y. D. Montarras, W. Wright, and F. Gros. 1980. Expression of myogenic differentiation and myotube formation by chick embryo myoblasts in the presence of sodium butyrate. Exp. Cell Res. 126:31-37.

14. Fischman, M. Y. D. Montarras, W. Wright, and F. Gros. 1980. Expression of myogenic differentiation and myotube formation by chick embryo myoblasts in the presence of sodium butyrate. Exp. Cell Res. 126:31-37.

15. Grunwald, G. B., R. E. M. Bromberg, N. J. Crowley, and J. Lilien. 1981. Enzymatic dissection of embryonic cell adhesive mechanisms. J. Cell Biol. 85:766-776.

16. Grunwald, G. B., R. E. M. Bromberg, N. J. Crowley, and J. Lilien. 1981. Enzymatic dissection of embryonic cell adhesive mechanisms. J. Cell Biol. 85:766-776.

17. Hirota, H. S. Ozaki, K. Tokunaga, and T. S. Okada. 1979. Experimental teratocarcinoma cell adhesion: identification of a nonintegral membrane protein of early mouse embryo. Proc. Natl. Acad. Sci. USA. 80:6074-6078.

18. Horwitz, A. F., K. A. Knudsen, C. H. Damsky, C. Decker, C. A. Buck, and N. T. Neff. 1984. Adhesion-related integral membrane glycoproteins identified by monoclonal antibodies. Mol. Immunol. 21:1191-1198.

19. Huntington, A. F., and A. F. Horwitz. 1984. Calcium-dependent cell-cell adhesion molecules common to hepatocytes and teratocarcinoma stem cells. J. Cell Biol. 97:944-948.

20. Knudsen, K. A., A. F. Horwitz. 1977. Tandem events in myoblast fusion. Dev. Biol. 58:328-338.

21. Knudsen, K. A., and A. F. Horwitz. 1978. Differential inhibition of myoblast fusion. Dev. Biol. 66:294-307.

22. Konigsberg, H., R. K. Rodland, and A. P. Somlyo. 1975. Effects of calcium on myogenic cell-cell adhesion. J. Cell Biol. 67:826-834.

23. Krupinski, J. A., and E. Anderson. 1975. Calcium and myoblast fusion. Cell. 32:257-265.

24. Marks, D. R. 1984. Specific blockers of myoblast fusion inhibit a soluble and not the membrane-associated metalloproteinase in myoblasts. J. Biol. Chem. 259:5390-5399.

25. Magnan, J. L., W. A. Thomas, and M. S. Steinberg. 1982. Two distinct adhesion molecules in embryonic neural retina cells. Dev. Biol. 81:96-105.

26. Marnett, J. L., J. Trotter, J. Keller, and E. Munar. 1973. Inhibition of cellular differentiation by trifluoperazine. J. Cell Biol. 58:161-167.

27. Neff, N. T., C. Lowry, C. Decker, A. Tovar, C. Damsky, C. Buck, and A. F. Horwitz. 1982. A monoclonal antibody detaches embryonic skeletal muscle from extracellular matrices. J. Cell Biol. 95:654-666.